H.C. Wainwright raised the firm’s price target on Adma Biologics (ADMA) to $26 from $18 and keeps a Buy rating on the shares. The company reported a substantial top- and bottom-line outperformance and its guidance was increased yet again, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA: